Research progress of RNA alternative splicing mechanisms and their roles in cancer therapy
10.11665/j.issn.1000-5048.2005022401
- VernacularTitle:RNA可变剪接机制及其在肿瘤治疗中的研究进展
- Author:
Xinxin HUANG
1
;
Mingzhu TANG
;
Duowei WANG
Author Information
1. 中国药科大学基础医学与临床药学学院, 南京 211198;中国药科大学转化医学研究院, 南京 210009
- Publication Type:Journal Article
- Keywords:
alternative splicing;
spliceosome;
cancer therapy;
targeted drugs;
antisense oligonucleotide therapy;
drug resistance therapy
- From:
Journal of China Pharmaceutical University
2026;57(2):155-162
- CountryChina
- Language:Chinese
-
Abstract:
Alternative splicing (AS), a critical mechanism in gene expression regulation, is essential for cellular physiological processes such as proliferation, metabolism, and apoptosis via generating diverse mRNA isoforms and expanding protein diversity. In the field of oncology, AS has been significantly implicated in the regulation of various biological processes involved in tumorigenesis and cancer progression. Specific mutations or expression changes in splicing factors, such as SF3B1, SRSF2, and U2AF1, play key roles in multiple types of cancer. This review summarizes novel therapeutic strategies for cancer targeting alternative splicing, including inhibiting spliceosome components, antisense oligonucleotide (ASO) therapy, and approaches to overcome drug resistance and immune evasion in cancer. These strategies, which modulate the activity of splicing factors and RNA-modifying enzymes, show promise in addressing chemoresistance and enhancing the efficacy of immunotherapy. This review provides a comprehensive exploration of alternative splicing mechanisms, their role in cancer, and their potential as a therapeutic target, highlighting the importance of alternative splicing in cancer research and therapy.
